Lemaitre Vascular Inc(LMAT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 29.52 | EPS (ttm) | 2.81 | Insider Own | 6.91% | Shs Outstand | 22.9M | Perf Week | -0.96% |
| Market Cap | 1.90B | Forward P/E | 26.07 | EPS next Y | 10.66% | Insider Trans | -3.56% | Shs Float | 21.3M | Perf Month | -0.02% |
| Enterprise Value | 1.71B | PEG | 2.34 | EPS next Q | 0.69 | Inst Own | 100.15% | Short Float | 8.34% | Perf Quarter | -18.91% |
| Income | 0.07B | P/S | 7.22 | EPS this Y | 13.99% | Inst Trans | 2.78% | Short Ratio | 5.49 | Perf Half Y | -22.74% |
| Sales | 0.26B | P/B | 4.51 | EPS next 5Y | 11.16% | ROA | 10.78% | Short Interest | 1.78M | Perf YTD | 2.18% |
| Book/sh | 18.38 | P/C | 5.04 | EPS past 3/5Y | 39.34% 19.43% | ROE | 16.77% | 52W High | -29.78% ($118.01) | Perf Year | -7.45% |
| Cash/sh | 16.45 | P/FCF | 25.67 | Sales past 3/5Y | 15.58% 14.05% | ROIC | 10.82% | 52W Low | 5.94% ($78.22) | Perf 3Y | 74.83% |
| Dividend Est. | $1 (1.21%) | EV/EBITDA | 19.46 | EPS Y/Y TTM | 38.09% | Gross Margin | 71.27% | Volatility(W/M) | 2.12% 2.68% | Perf 5Y | 47.32% |
| Dividend TTM | 0.95 | EV/Sales | 6.51 | Sales Y/Y TTM | 11.85% | Oper. Margin | 29.46% | ATR (14) | 2.08 | Perf 10Y | 284.01% |
| Dividend Ex-Date | 2026/8/20 | Quick Ratio | 13.96 | EPS Q/Q | 15.47% | Profit Margin | 25.02% | RSI (14) | 51.49 | Recom | 2 |
| Dividend Gr. 3/5Y | 16.96% 16.05% | Current Ratio | 15.89 | Sales Q/Q | 9.57% | SMA20 | 1.06% ($82) | Beta | 0.5 | Target Price | $107 |
| Payout | 31.77% | Debt/Eq | 0.45 | Earnings | 2026/11/4 | SMA50 | 2.06% ($81.2) | Rel Volume | 1.12 | Prev Close | $83.79 |
| Employees | 655 | LT Debt/Eq | 0.44 | EPS/Sales Surpr. | -8.27% -1.53% | SMA200 | -12.29% ($94.48) | Avg Volume(3M) | 0.32M | Price | $82.87 |
| IPO | 2006/10/19 | Option/Short | Yes/Yes | Trades | 5268 | Volume | 360,755 | Change | -1.1% |
🩸 This is a US-based company that develops and supplies medical devices for the treatment of peripheral vascular diseases. It offers a diverse range of niche medical devices used in peripheral vascular surgery, including vascular grafts and shunts, catheters, and patches, and grows through a specialized product portfolio and acquisition strategy targeting vascular surgeons. The company has established itself as a medical device provider focused on the peripheral vascular field.
Over the past 1 year, on the lower side
30% below its 1-year high.
Traded about as much as usual. That is 112% of its average volume.
Next earnings report: November 4
6 days to go.
LMAT makes money exceptionally well
Of every $100 in sales, $29.46 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +14.0% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,946. Peers typically go for $1,589. Compared with its own 5-year average, it is 34% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +47.3%. The S&P 500 did +69% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 1.21% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 100.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #24 of 51 in the industry
Based on market cap of $2B.
FAQ
What kind of company is LMAT?
LMAT belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of LMAT?
The market cap of LMAT is approximately $1.9B, ranking 2,102 within its sector.
Does LMAT pay dividends?
LMAT has a dividend yield of approximately 1.21%, with an annual dividend of $1.00.
What is the P/E ratio of LMAT?
LMAT has a P/E ratio of approximately 29.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LMAT?
LMAT has recorded a 52-week high of $118.01 and a low of $78.22.